The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
Open accessAbstract
Background Invasive candidosis is increasingly prevalent in seriously ill patients. Our aim was to compare micafungin with liposomal amphotericin B for the treatment of adult patients with candidaemia or invasive candidosis.Methods We did a double-blind, randomised, multinational non-inferiority study to compare micafungin (100 mg/day) with liposomal amphotericin B (3 mg/kg per day) as first-line treatment of candidaemia and invasive candidosis. The primary endpoint was treatment success, defined as both a clinical and a mycological response at the end of treatment. Primary analyses were done on a per-protocol basis. This trial is registered with ClinicalTrials.gov, number NCT00106288.Findings 264 individuals were randomly assigned to treatment with micafungin; 267 were randomly assigned to receive liposomal amphotericin B. 202 individuals in the micafungin group and 190 in the liposomal amphotericin B group were included in the per-protocol analyses. Treatment success was observed for 181 (89.6%) patients treated with micafungin and 170 (89.5%) patients treated with liposomal amphotericin B. The difference in proportions, after stratification by neutropenic status at baseline, was 0.7% (95% CI -5.3 to 6.7). Efficacy was independent of the Candida spp and primary site of infection, as well as neutropenic status, APACHE II score, and whether a catheter was removed or replaced during the study. There were fewer treatment-related adverse events--including those that were serious or led to treatment discontinuation--with micafungin than there were with liposomal amphotericin B.Interpretation Micafungin was as effective as--and caused fewer adverse events than--liposomal amphotericin B as first-line treatment of candidaemia and invasive candidosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [140]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [140]
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [140]
In the citing paper
“Safety and tolerability were similar between the two groups and were consistent with the reported safety profile of echinocandin class drugs. 22-26”
In the citing paper
“In both trials, echinocandins were associated with fewer adverse events, including serious events leading to drug discontinuation.”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [21]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Schwartz, G. J., Brion, L. P., & Spitzer, A. (1987) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(16)36251-4 · Cited by 1,726
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Wingard, J. R., White, M. H., Anaissie, E., Raffalli, J., Goodman, J., Arrieta, A., & L Amph/ABLC Collaborative Study Group (2000) · Clinical Infectious Diseases · doi:10.1086/317451 · Cited by 527
Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Self-citationAntifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States
Ostrosky-Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N., Kauffman, C. A., Cleary, J., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3149-3154.2003 · Cited by 498
Self-citationRex, J. H., Pappas, P. G., Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S., Brass, C., Vazquez, J. A., Chapman, S. W., Horowitz, H. W., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374850 · Cited by 495
Mortality and Costs of Acute Renal Failure Associated with Amphotericin B Therapy
Bates, D. W., Su, L., Yu, D. T., Chertow, G. M., Seger, D. L., Gomes, D. R. J., Dasbach, E. J., & Platt, R. (2001) · Clinical Infectious Diseases · doi:10.1086/319211 · Cited by 451
Research works printed but not linked: 2
- Reboli A, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for treatment of candidaemia and invasive candidiasis. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, USA; 2005. Abstract M-718.
- Anaissie EJ, Uzun C, Singer GP, et al. Amphotericin B lipid complex versus amphotericin B for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicentre trial. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL, USA; September, 1995. Abstract LM21.
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Self-citationMermel, L. A., Allon, M., Bouza, E., Craven, D. E., Flynn, P., O'Grady, N. P., Raad, I. I., Rijnders, B. J. A., Sherertz, R. J., & Warren, D. K. (2009) · Clinical Infectious Diseases · doi:10.1086/599376 · Cited by 3,638
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Self-citationPappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.26 · Cited by 1,636
Self-citationKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315
Metadata
- Authors
- Kuse, E.-R., Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J. S., Freire, A., Ramasubramanian, V., Demeyer, I., Nucci, M., Leelarasamee, A., Jacobs, F., Decruyenaere, J., Pittet, D., Ullmann, A. J., Ostrosky-Zeichner, L., Lortholary, O., Koblinger, S., Diekmann-Berndt, H., & Cornely, O. A.
- Affiliations
- Khon Kaen University (TH)
- Charité – Universitätsmedizin Berlin (DE)
- Hospital São Lucas da PUCRS (BR)
- Dayanand Medical College & Hospital (IN)
- Grupo Santa Casa de Belo Horizonte (BR)
- Apollo Hospitals (IN)
- Onze Lieve Vrouwziekenhuis Hospital (BE)
- Siriraj Hospital (TH)
- Erasmus Hospital (BE)
- Ghent University Hospital (BE)
- University Hospital of Geneva (CH)
- Johannes Gutenberg University Mainz (DE)
- Hôpital Necker-Enfants Malades (FR)
- Astellas Pharma (Germany) (DE)
- University Hospital Cologne (DE)
- Corresponding author
- Cornely, Oliver A
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2007-05
- Volume
- 369
- Issue
- 9572
- Pages
- 1519-1527
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2121247465
- Cited by
- 692
- References
- 22
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 10 · 2023: 12 · 2022: 9 · 2021: 21 · 2020: 19 · 2019: 29 · 2018: 34 · 2017: 25 · 2016: 25 · 2015: 37 · 2014: 37 · 2013: 43 · 2012: 53
- FWCI
- 51.38
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- micafungin, liposomal amphotericin B, candidemia, antifungal therapy, treatment success, non-inferiority, neutropenia, adverse events, Candida species
- MeSH terms
- Micafungin, Adolescent, Adult, Aged, Aged, 80 and over, Amphotericin B, Antifungal Agents, Candidiasis, Double-Blind Method, Female, Humans, Lipoproteins, Male, Microbial Sensitivity Tests, Middle Aged, Peptides, Cyclic, Treatment Outcome, APACHE, Echinocandins, Lipopeptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. https://app.cochat.ai/papers/10.1016/s0140-6736(07)60605-9
- The paper
- Kuse, E.-R., Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J. S., Freire, A., Ramasubramanian, V., Demeyer, I., Nucci, M., Leelarasamee, A., Jacobs, F., Decruyenaere, J., Pittet, D., Ullmann, A. J., Ostrosky-Zeichner, L., Lortholary, O., Koblinger, S., . . . Cornely, O. A. (2007). Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. The Lancet. https://doi.org/10.1016/s0140-6736(07)60605-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.